(ESTA) Establishment Labs Holdings - Ratings and Ratios
Breast Implants, Tissue Expanders
ESTA EPS (Earnings per Share)
ESTA Revenue
Description: ESTA Establishment Labs Holdings
Establishment Labs Holdings Inc (NASDAQ:ESTA) is a Costa Rica-based company operating in the Health Care Supplies sub-industry. The companys common stock is listed on the NASDAQ exchange.
To evaluate the companys performance, we need to examine key economic drivers and KPIs. The medical device industry is driven by factors such as technological innovation, regulatory approvals, and adoption rates among healthcare providers. Key performance indicators for Establishment Labs may include revenue growth, gross margin expansion, and research and development (R&D) pipeline advancements.
The companys financials indicate significant investment in growth, reflected in a negative Return on Equity (RoE) of -240.67%. This suggests that the company is currently prioritizing growth over profitability, which is common in the medical device industry where R&D expenses are substantial. Market capitalization stands at $973.99M USD, indicating a moderate-sized company with potential for further growth or consolidation.
To assess the viability of Establishment Labs as a trading opportunity, we must consider the competitive landscape, product pipeline, and clinical trial outcomes. The companys ability to secure regulatory approvals, drive product adoption, and expand its customer base will be crucial in determining its future financial performance.
From a trading perspective, Establishment Labs stock price volatility, as measured by its Average True Range (ATR) and beta, suggests a moderate level of risk. Traders should monitor key support and resistance levels, as well as moving averages (SMA20, SMA50, SMA200), to identify potential trading opportunities.
ESTA Stock Overview
| Market Cap in USD | 1,112m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 2018-07-19 |
ESTA Stock Ratings
| Growth Rating | -43.3% |
| Fundamental | 19.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -25.6% |
| Analyst Rating | 4.50 of 5 |
ESTA Dividends
Currently no dividends paidESTA Growth Ratios
| Growth Correlation 3m | -22.4% |
| Growth Correlation 12m | -30.8% |
| Growth Correlation 5y | -45.4% |
| CAGR 5y | -14.06% |
| CAGR/Max DD 3y | -0.20 |
| CAGR/Mean DD 3y | -0.35 |
| Sharpe Ratio 12m | 0.47 |
| Alpha | -27.65 |
| Beta | 0.644 |
| Volatility | 61.27% |
| Current Volume | 313.9k |
| Average Volume 20d | 239.8k |
| Stop Loss | 35.3 (-5.8%) |
| Signal | -0.02 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-88.5m TTM) > 0 and > 6% of Revenue (6% = 10.6m TTM) |
| FCFTA -0.22 (>2.0%) and ΔFCFTA 17.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 83.66% (prev 95.30%; Δ -11.64pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.22 (>3.0%) and CFO -72.7m > Net Income -88.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (29.5m) change vs 12m ago 5.63% (target <= -2.0% for YES) |
| Gross Margin 67.24% (prev 66.04%; Δ 1.20pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 57.72% (prev 53.09%; Δ 4.63pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3.10 (EBITDA TTM -61.8m / Interest Expense TTM 23.1m) >= 6 (WARN >= 3) |
Altman Z'' -3.57
| (A) 0.45 = (Total Current Assets 229.2m - Total Current Liabilities 80.7m) / Total Assets 329.7m |
| (B) -1.46 = Retained Earnings (Balance) -482.0m / Total Assets 329.7m |
| warn (B) unusual magnitude: -1.46 — check mapping/units |
| (C) -0.23 = EBIT TTM -71.5m / Avg Total Assets 307.4m |
| (D) -0.18 = Book Value of Equity -56.5m / Total Liabilities 306.9m |
| Total Rating: -3.57 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 19.19
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield -5.79% = -2.89 |
| 3. FCF Margin -41.75% = -7.50 |
| 4. Debt/Equity 9.79 = -2.50 |
| 5. Debt/Ebitda -3.61 = -2.50 |
| 6. ROIC - WACC -35.73% = -12.50 |
| 7. RoE -240.7% = -2.50 |
| 8. Rev. Trend 19.34% = 0.97 |
| 9. Rev. CAGR 11.27% = 1.41 |
| 10. EPS Trend -11.61% = -0.29 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of ESTA shares?
Over the past week, the price has changed by -4.01%, over one month by +11.44%, over three months by +0.93% and over the past year by -11.41%.
Is Establishment Labs Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ESTA is around 31.99 USD . This means that ESTA is currently overvalued and has a potential downside of -14.63%.
Is ESTA a buy, sell or hold?
- Strong Buy: 5
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ESTA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 55.4 | 48% |
| Analysts Target Price | 55.4 | 48% |
| ValueRay Target Price | 35.3 | -5.8% |
Last update: 2025-09-05 04:41
ESTA Fundamental Data Overview
CCE Cash And Equivalents = 54.6m USD (Cash And Short Term Investments, last quarter)
P/S = 6.2655
P/B = 51.3157
Beta = 0.829
Revenue TTM = 177.4m USD
EBIT TTM = -71.5m USD
EBITDA TTM = -61.8m USD
Long Term Debt = 221.1m USD (from longTermDebt, last quarter)
Short Term Debt = 1.62m USD (from shortTermDebt, last quarter)
Debt = 222.8m USD (Calculated: Short Term 1.62m + Long Term 221.1m)
Net Debt = 169.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.28b USD (1.11b + Debt 222.8m - CCE 54.6m)
Interest Coverage Ratio = -3.10 (Ebit TTM -71.5m / Interest Expense TTM 23.1m)
FCF Yield = -5.79% (FCF TTM -74.1m / Enterprise Value 1.28b)
FCF Margin = -41.75% (FCF TTM -74.1m / Revenue TTM 177.4m)
Net Margin = -49.89% (Net Income TTM -88.5m / Revenue TTM 177.4m)
Gross Margin = 67.24% ((Revenue TTM 177.4m - Cost of Revenue TTM 58.1m) / Revenue TTM)
Tobins Q-Ratio = -22.64 (set to none) (Enterprise Value 1.28b / Book Value Of Equity -56.5m)
Interest Expense / Debt = 2.67% (Interest Expense 5.96m / Debt 222.8m)
Taxrate = 21.0% (US default)
NOPAT = -71.5m (EBIT -71.5m, no tax applied on loss)
Current Ratio = 2.84 (Total Current Assets 229.2m / Total Current Liabilities 80.7m)
Debt / Equity = 9.79 (Debt 222.8m / last Quarter total Stockholder Equity 22.8m)
Debt / EBITDA = -3.61 (Net Debt 169.9m / EBITDA -61.8m)
Debt / FCF = -3.01 (Debt 222.8m / FCF TTM -74.1m)
Total Stockholder Equity = 36.8m (last 4 quarters mean)
RoA = -26.85% (Net Income -88.5m, Total Assets 329.7m )
RoE = -240.7% (Net Income TTM -88.5m / Total Stockholder Equity 36.8m)
RoCE = -27.72% (Ebit -71.5m / (Equity 36.8m + L.T.Debt 221.1m))
RoIC = -28.38% (NOPAT -71.5m / Invested Capital 251.9m)
WACC = 7.34% (E(1.11b)/V(1.33b) * Re(8.39%)) + (D(222.8m)/V(1.33b) * Rd(2.67%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.19 | Cagr: 1.69%
Discount Rate = 8.39% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -74.1m)
Revenue Correlation: 19.34 | Revenue CAGR: 11.27%
Rev Growth-of-Growth: 23.81
EPS Correlation: -11.61 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 19.17
Additional Sources for ESTA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle